Asian Conference on Tumor Ablation Guidelines for Hepatocellular Carcinoma.

IF 11.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Liver Cancer Pub Date : 2025-03-03 DOI:10.1159/000544976

Shuichiro Shiina, Ryosuke Tateishi, Joon Il Choi, So Yeon Kim, Zhiqiang Meng, Lujun Shen, Sheng-Nan Lu, Jen-I Hwang, Maki Tobari, Hitoshi Maruyama, Terguunbileg Batsaikhan, Qing Deng, Lariza Marie Canseco, Yoshinari Asaoka, Shi-Ming Lin, Kai-Wen Huang, Hyunchul Rhim, Ping Liang, Uei Pua, Masatoshi Tanaka, Peihong Wu

{"title":"Asian Conference on Tumor Ablation Guidelines for Hepatocellular Carcinoma.","authors":"Shuichiro Shiina, Ryosuke Tateishi, Joon Il Choi, So Yeon Kim, Zhiqiang Meng, Lujun Shen, Sheng-Nan Lu, Jen-I Hwang, Maki Tobari, Hitoshi Maruyama, Terguunbileg Batsaikhan, Qing Deng, Lariza Marie Canseco, Yoshinari Asaoka, Shi-Ming Lin, Kai-Wen Huang, Hyunchul Rhim, Ping Liang, Uei Pua, Masatoshi Tanaka, Peihong Wu","doi":"10.1159/000544976","DOIUrl":null,"url":null,"abstract":"<p><p>Globally, the incidence and associated mortality of primary liver cancer have been steadily increasing. Currently, 80% of cases are found in Asia. Curative resection is applicable in only 20% of patients; therefore, various nonsurgical treatment modalities have been developed. Image-guided percutaneous liver tumor ablation is regarded as the best option for treating early-stage hepatocellular carcinoma (HCC). However, skills and knowledge in ablation can vary among operators. Furthermore, Asia has the highest number of ablation procedures for HCC and the largest number of doctors performing ablation worldwide. Thus, the Asian Conference on Tumor Ablation has developed guidelines for HCC. These guidelines will discuss indications, pre-ablative diagnosis and planning, techniques, peri-ablative management, evaluation of therapeutic effectiveness, complications, post-ablative follow-up, prevention of recurrence, and treatment of recurrence for HCC.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":" ","pages":"1-27"},"PeriodicalIF":11.6000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11998674/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000544976","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Globally, the incidence and associated mortality of primary liver cancer have been steadily increasing. Currently, 80% of cases are found in Asia. Curative resection is applicable in only 20% of patients; therefore, various nonsurgical treatment modalities have been developed. Image-guided percutaneous liver tumor ablation is regarded as the best option for treating early-stage hepatocellular carcinoma (HCC). However, skills and knowledge in ablation can vary among operators. Furthermore, Asia has the highest number of ablation procedures for HCC and the largest number of doctors performing ablation worldwide. Thus, the Asian Conference on Tumor Ablation has developed guidelines for HCC. These guidelines will discuss indications, pre-ablative diagnosis and planning, techniques, peri-ablative management, evaluation of therapeutic effectiveness, complications, post-ablative follow-up, prevention of recurrence, and treatment of recurrence for HCC.

查看原文本刊更多论文

亚洲肝癌肿瘤消融指南会议。

在全球范围内，原发性肝癌的发病率和相关死亡率一直在稳步上升。目前，80%的病例发生在亚洲。根治性切除仅适用于20%的患者；因此，发展了多种非手术治疗方式。图像引导下经皮肝肿瘤消融被认为是治疗早期肝细胞癌（HCC）的最佳选择。然而，消融的技能和知识因操作人员而异。此外，亚洲的HCC消融手术数量最多，实施消融手术的医生数量也最多。因此，亚洲肿瘤消融会议制定了HCC治疗指南。这些指南将讨论HCC的适应症、消融前诊断和计划、技术、消融周围管理、治疗效果评估、并发症、消融后随访、复发预防和复发治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Liver Cancer Medicine-Oncology

CiteScore

20.80

自引率

7.20%

发文量

审稿时长

16 weeks

期刊介绍： Liver Cancer is a journal that serves the international community of researchers and clinicians by providing a platform for research results related to the causes, mechanisms, and therapy of liver cancer. It focuses on molecular carcinogenesis, prevention, surveillance, diagnosis, and treatment, including molecular targeted therapy. The journal publishes clinical and translational research in the field of liver cancer in both humans and experimental models. It publishes original and review articles and has an Impact Factor of 13.8. The journal is indexed and abstracted in various platforms including PubMed, PubMed Central, Web of Science, Science Citation Index, Science Citation Index Expanded, Google Scholar, DOAJ, Chemical Abstracts Service, Scopus, Embase, Pathway Studio, and WorldCat.